Share Name Share Symbol Market Type Share ISIN Share Description
Woodford Patient Capital Trust LSE:WPCT London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.30p +0.40% 74.50p 1,236,498 16:35:05
Bid Price Offer Price High Price Low Price Open Price
74.20p 74.60p 75.60p 74.00p 74.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -3.4 -0.4 - 616.12

Woodford Patient Capital (WPCT) Latest News (2)

More Woodford Patient Capital News
Woodford Patient Capital Takeover Rumours

Woodford Patient Capital (WPCT) Share Charts

1 Year Woodford Patient Capital Chart

1 Year Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Woodford Patient Capital (WPCT) Discussions and Chat

Woodford Patient Capital Forums and Chat

Date Time Title Posts
22/5/201820:39::: WOODFORD PATIENT CAPITAL TRUST :::3,054
24/4/201811:31Woodford Patient Capital Trust197

Add a New Thread

Woodford Patient Capital (WPCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:05:4574.5025,00018,625.00O
15:35:0574.5026,84720,001.02UT
15:21:2774.761,4011,047.36O
15:21:0074.902,5781,930.92AT
15:21:0074.902,2321,671.77AT
View all Woodford Patient Capital trades in real-time

Woodford Patient Capital (WPCT) Top Chat Posts

DateSubject
22/5/2018
09:20
Woodford Patient Capital Daily Update: Woodford Patient Capital Trust is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker WPCT. The last closing price for Woodford Patient Capital was 74.20p.
Woodford Patient Capital Trust has a 4 week average price of 73.50p and a 12 week average price of 70.50p.
The 1 year high share price is 106.50p while the 1 year low share price is currently 70.50p.
There are currently 827,000,000 shares in issue and the average daily traded volume is 1,975,318 shares. The market capitalisation of Woodford Patient Capital Trust is £616,115,000.
15/5/2018
08:58
daffyjones: Why did you sell on the next working day, when the share price was still massively below the launch price? Surely if Woody is such a biotech genius, you'd expect the share price to rise further at least to get back where it started at 100p. Why did you turn your back on this guaranteed future profit? Could it be that you don't actually have faith in the long term prospects of this Patient Capital Trust? Thanks for joining us bears! Glad you saw reason in the end.
02/5/2018
23:06
saltraider: Hands up ... I am really not a 'harsh' sort of a person. Apologies to @orinocor for being excessively terse. The trouble is that there are a fair few people around and about who are trying to manipulate the WPCT share price ... and using some pretty dubious means to do it. They are shorting WPCT and trying to use other 'communications' avenues to add to the pressure on the price at the same time. That includes pushing blatantly fake news. When you step in (@orinocor) and make negative statements based on apparently zero knowledge of the basic WPCT concept, you are just accidentally (and ignorantly ... sorry!) aiding and abetting the manipulators.
16/4/2018
21:04
daffyjones: Andyj: "Having bought at 74p, I was not expecting such a quick return of 14% in a matter of weeks" IQ51: "I bought WPCT shares just after 8.00 a.m. on February 6 2018. They cost me 73p each." Mazarin: "I bought when it was much less." Mochyn: "I and the other more intelligent guys here are sitting on at least a 16% rise" Wow!!! Got to love how all the WPCT rampers suddenly claim to have bought in at 73-74p, right at the very bottom. Who knew we had so many expert falling-knife catchers here?! They all managed to time their purchases perfectly right at the trough of the share price. But for some reason they were in this thread for months beforehand ramping WPCT at 90p and 95p and 100p, without apparently actually having made any purchases at that price. How curious! TROLL-FIB ALERT!!!
11/4/2018
18:36
daffyjones: Really bizarre how all the WPCT rampers have come out of the woodwork to gloat about a 9% rise in the share price. The shares are still 17% below their launch price. WPCT will need to rise by 45% from its current level in order to meet its cumulative hurdle for Woody to receive a fee. By any reckoning, WPCT is still far underperforming against expectations and against the general market. Yes it's nice that the share price has risen to 83.4p but don't overdo the celebrations. Don't worry, when it gets back to 100p I'll be the first to congratulate you all on finally breaking even.
05/4/2018
21:32
daffyjones: Some positive press coverage at last for Woody! To be fair he was started from a terrible position in Feb. [Begins:] An unexpected recovery for Woodford Patient Capital Trust has made the struggling investment trust the surprise top performer among the sector specialist funds in March, albeit amid a substantial slump for the wider biotech and pharmaceuticals sector. WPCT was the top performer out of the 13 closed end funds investing in wholly or largely in biotech or healthcare, in terms of both NAV and share price performance, in March, and was a mid-range performer over the first quarter. This contrasts markedly with its poor longer term performance for NAV and share price in absolute terms and in comparison with benchmarks and peers. WPCT achieved a 0.6% rise in NAV and a 6.7% increase in share price in the month, which compared with negative 1-5% changes in NAV for all the other funds and 1.5-6.5% declines in price, for all but one other fund.
25/3/2018
11:12
ttg100: The article in full "Shares in the Woodford Patient Capital (WPCT) investment trust have surged after top holding Prothena (PRTA.O) announced a tie-up with biotech giant Celgene (CELG.O) in a deal that could be worth as much as $2.2 billion (£1.6 billion). Shares in the trust jumped 7.4% to 78.2p after Prothena, which accounts for 9.8% of the portfolio, announced it would collaborate with Celgene to develop treatments for neurodegenerative diseases. Shares in US-listed Prothena, also the seventh largest holding in Woodford's flagship Woodford Equity Income fund, surged 23% in aftermarket trading. Prothena is a 1.9% position in the Woodford Incoms Focus fund. Prothena will receive a $100 million upfront payment from Celgene and a $50 million equity investment from the biotech group, as well as the rights to royalties on the sales of any products that result. Total payments to the company as part of the tie-up, focused on three proteins, could amount to $2.2 billion. For each of the three drugs in development, Celgene would have to pay $80 million if it exercised US rights, $55 million for global rights, and up to $562.5 million as the drugs hit regulatory and commercial milestones. A spokesman for Woodford Investment Management said: 'The deal makes perfect sense for Prothena and allows its research and development engine to be funded by one of the leading US biotech companies.' Shares in Prothena have been a drag on performance of both the Woodford Patient Capital trust and Woodford Equity Income fund, after the stock came under attack from short-sellers Kerrisdale Capital. The shares suffered a further sell-off after a delay to a trial of its flagship drug, a potential therapy for AL Amyloidosis in November last year. Even with today's surge, the shares have lost nearly half their value over the last six months. But Woodford has stuck by the stock, saying the market's reaction to the delay was misguided and that he was 'encouraged' by progress on the drug. Woodford has been enduring one of the most challenging periods of his fund management career, with his flagship Woodford Equity Income fund languishing at the bottom of the UK Equity Income sector over one year, hurt by heavy share price falls of top holdings like Provident Financial (PFG) and Capita (CPI). His Woodford Patient Capital trust has also struggled, and even with today's jump the shares remain well below their 100p price at flotation in April 2015. The trust also received a boost yesterday from its second largest holding, unquoted Oxford Nanopore, which represents 9.5% of the portfolio. The handheld DNA test maker's £100 million fundraising took its valuation to £1.5 billion, up from £1.25 billion at its last financing round in 2016. Oxford Nanopore is also a 1.4% holding in the Woodford Equity Income fund, which has also benefited from the news through its top 10 holding in IP Group (IPO), which owns 18.3% of Oxford Nanopore. Shares in IP Group are up 10% over the last two days. Another Woodford stock, Softcat (SCTS) is down 12% today, however, as the IT infrastructure company, whose shares had nearly doubled over the last 12 months, succumbed to profit-taking after half-year results. Softcat accounts for 2.2% of the Woodford Income Focus fund."
22/3/2018
09:19
ttg100: "Shares in the Woodford Patient Capital (WPCT + Add to favourites ) investment trust have surged after top holding Prothena (PRTA.O) announced a tie-up with biotech giant Celgene (CELG.O) in a deal that could be worth as much as $2.2 billion (£1.6 billion). Shares in the trust jumped 7.4% to 78.2p after Prothena, which accounts for 9.8% of the portfolio, announced it would collaborate with Celgene to develop treatments for neurodegenerative diseases. Shares in US-listed Prothena, also the seventh largest holding in Woodford's flagship Woodford Equity Income + Add to favourites fund, surged 23% in aftermarket trading. Prothena is a 1.9% position in the Woodford Incoms Focus + Add to favourites fund. Prothena will receive a $100 million upfront payment from Celgene and a $50 million equity investment from the biotech group, as well as the rights to royalties on the sales of any products that result. Total payments to the company as part of the tie-up, focused on three proteins, could amount to $2.2 billion. For each of the three drugs in development, Celgene would have to pay $80 million if it exercised US rights, $55 million for global rights, and up to $562.5 million as the drugs hit regulatory and commercial milestones. A spokesman for Woodford Investment Management said: 'The deal makes perfect sense for Prothena and allows its research and development engine to be funded by one of the leading US biotech companies.' Shares in Prothena have been a drag on performance of both the Woodford Patient Capital trust and Woodford Equity Income fund, after the stock came under attack from short-sellers Kerrisdale Capital. The shares suffered a further sell-off after a delay to a trial of its flagship drug, a potential therapy for AL Amyloidosis in November last year. Even with today's surge, the shares have lost nearly half their value over the last six months. But Woodford has stuck by the stock, saying the market's reaction to the delay was misguided and that he was 'encouraged' by progress on the drug. Woodford has been enduring one of the most challenging periods of his fund management career, with his flagship Woodford Equity Income fund languishing at the bottom of the UK Equity Income sector over one year, hurt by heavy share price falls of top holdings like Provident Financial (PFG + Add to favourites ) and Capita (CPI + Add to favourites ). His Woodford Patient Capital trust has also struggled, and even with today's jump the shares remain well below their 100p price at flotation in April 2015. The trust also received a boost yesterday from its second largest holding, unquoted Oxford Nanopore, which represents 9.5% of the portfolio. The handheld DNA test maker's £100 million fundraising took its valuation to £1.5 billion, up from £1.25 billion at its last financing round in 2016. Oxford Nanopore is also a 1.4% holding in the Woodford Equity Income + Add to favourites fund, which has also benefited from the news through its top 10 holding in IP Group (IPO + Add to favourites ), which owns 18.3% of Oxford Nanopore. Shares in IP Group are up 10% over the last two days. Another Woodford stock, Softcat (SCTS + Add to favourites ) is down 12% today, however, as the IT infrastructure company, whose shares had nearly doubled over the last 12 months, succumbed to profit-taking after half-year results. Softcat accounts for 2.2% of the Woodford Income Focus fund."
04/3/2018
15:54
daffyjones: @topvest "Can someone name an unsuccessful investment that Woodford admitted he got it wrong and actually sold rather than being anchored to his original investment thesis?" Rolls Royce comes to mind. He was a long term holder, owning 2.3% of the company, but the share price fell from a high of £12.71 in January 2014 to just £5.13 in December 2015. Over those two years Woodford posted a number of his usual bullish statements claiming the market was wrong and he was right - e.g. in October 2014 when the price was still over £9 he stated "the market has clearly focused on the short-term disappointment of last week’s statement, we believe that in so doing, it is ignoring some meaningful long-term positives. The shares are now more attractively valued than they have been in some time". He eventually sold his entire stake in Rolls Royce right at the bottom, in December 2015, when the share price was just over £5, citing "material downgrades to profit and cash expectations, and to such an extent that it is now likely that the dividend will be cut in 2016. This has shaken my confidence in the investment case and so the position has been sold across all mandates." RR shares are now trading at £8.17, 60% higher than when Woodford sold up. He managed to time it so he sold at the very bottom.
21/2/2018
10:20
hpcg: bookbroker - If one is a long term large investor in large cap companies it is irrational not to lend at least some stock. Not only does it provide extra income, but also an exit mechanism should one want to. This isn't Woodford's problem at all. His problem is his stock picks in the first place. He is picking good dividend payers on low valuations by profit. He does not apparently look at debt and EV related metrics, return metrics, operational metrics, or cash related metrics. It is beyond naive in this day and age. p1nk - I don't think IFAs are likely to promote this trust, more use the Woodford name for certain types of retail client. It isn't just IFAs, Hargreaves Lansdown are very big on the named fund manager concept; see this promotional piece on their from page: httPs://www.hl.co.uk/funds/five-investment-ideas-2018 Woodford funds are still in their Wealth 150+ list despite 4th quartile performance. jonwig - Syncona looks like it could (stress on the could) be a massive short, based on the disconnect between the NAV and the share price. Dividend adjusted NAV direction and relative discount are the only two metrics to sensibly judge a trust. One way of using trusts is to buy when NAV is consistently increasing as that suggests the investment style is now in vogue and money flow is your friend. Lucky Mouse has some excellent work on his IT trust board (ticker IT). On that count the investor in SYNC are way less rational than WPCT investors. The NAV started falling in October, yet the share price carried on up. Unless there is hidden success not counted for in the NAV, for example an exciting phase II trial result in a portfolio company, it looks absolutely mad.
14/3/2016
14:25
dr biotech: I am pretty sure that he has all his money invested in either the WPCT or his equity funds. He is doing a live webcast as I type. NEIL WOODFORD says: Today 2:00 pm Kelvin (and others that have asked similar questions), The weakness of the WPCT share price and NAV since the start of 2016 has been the product of the pretty severe sell-off in shares across healthcare, biotech and early-stage quoted stocks, both here in the UK and in the US. Much of this, we believe to be driven by short-term positioning and rotational activity amongst the fund management community. We don’t believe that it is driven by a correction of over-valuation, nor by a deterioration in fundamentals. We remain very pleased with the underlying progress of the businesses in which we have invested in the trust. Indeed, in what has been a pretty short space of time since launch, our expectations for the underlying performance of many businesses in the portfolio have been exceeded. This is a long-term vehicle. We hope to deliver good performance in the short-term but believe we should be judged over the 3 to 5 year time scale we have talked about consistently since launch. Kind regards Neil
Woodford Patient Capital share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180522 21:04:17